A radical approach to achieve complete cytoreductive surgery improve survival of patients with advanced ovarian cancer.


Journal

Journal of visceral surgery
ISSN: 1878-7886
Titre abrégé: J Visc Surg
Pays: France
ID NLM: 101532664

Informations de publication

Date de publication:
Apr 2020
Historique:
pubmed: 16 12 2019
medline: 4 5 2021
entrez: 16 12 2019
Statut: ppublish

Résumé

Cytoreductive surgery of locally advanced ovarian cancer has evolved in the last few years from surgery to remove macroscopic residual disease (<1cm; R2b) to macroscopic complete cytoreductive surgery with no gross residual disease (R1). The aim of this study was to evaluate the impact of the adoption of a maximalist surgical approach on postoperative complications, disease recurrence and survival. This was a retrospective study using prospectively collected data on patients who received either conservative approach (CA) or radical approach (RA) surgical treatment for primary ovarian cancer stage IIIc/IVa/IVb between June 2006 and June 2013. Data for 114 patients were included, 33 patients in the CA group and 68 patients in the RA group were consequently analysed. In the RA group, operative time was longer, in relation to more complex surgical procedures; with more blood losses and a higher rate of compete macroscopic resection. Totally, 77% of the patients had postoperative complications, with more grade I/II complications in the RA group but the same rates of grade III/IV complications in the both groups (P=0.14). For all patient study population, the overall and disease-free survivals were improved in case of no macroscopic residual disease. Overall survival was improved in the RA group (P=0.05), with no difference in terms of disease-free survival (P=0.29) CONCLUSION: A radical approach in advanced ovarian cancer allows a higher rate of complete cytoreductive surgery impacting overall survival. However, a non-significant trend for increased mild complications (grade I/II) rate is observed in this group.

Identifiants

pubmed: 31837942
pii: S1878-7886(19)30194-8
doi: 10.1016/j.jviscsurg.2019.12.002
pii:
doi:

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

79-86

Informations de copyright

Copyright © 2019. Published by Elsevier Masson SAS.

Auteurs

G Liberale (G)

Surgical Oncology, Institut Jules-Bordet, Université libre de Bruxelles, 121, boulevard de Waterloo, 1000 Brussels, Belgium. Electronic address: gabriel.liberale@bordet.be.

C-F Pop (CF)

Surgical Oncology, Institut Jules-Bordet, Université libre de Bruxelles, 121, boulevard de Waterloo, 1000 Brussels, Belgium.

L Polastro (L)

Medical Oncology, Institut Jules-Bordet, Université libre de Bruxelles, 1000 Brussels, Belgium.

J Kerger (J)

Medical Oncology, Institut Jules-Bordet, Université libre de Bruxelles, 1000 Brussels, Belgium.

M Moreau (M)

Statistics Department, Institut Jules-Bordet, Université libre de Bruxelles, 1000 Brussels, Belgium.

M Chintinne (M)

Pathology Department, Institut Jules-Bordet, Université libre de Bruxelles, 1000 Brussels, Belgium.

D Larsimont (D)

Pathology Department, Institut Jules-Bordet, Université libre de Bruxelles, 1000 Brussels, Belgium.

J M Nogaret (JM)

Surgical Oncology, Institut Jules-Bordet, Université libre de Bruxelles, 121, boulevard de Waterloo, 1000 Brussels, Belgium.

I Veys (I)

Surgical Oncology, Institut Jules-Bordet, Université libre de Bruxelles, 121, boulevard de Waterloo, 1000 Brussels, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH